Sections

DDx

Diagnostic Considerations

Also consider the following:

Hypothyroidism
Hyperthyroidism
Hypopituitarism
Diabetes mellitus
Sézary syndrome
Lymphoma
Protein malnutrition
Iron deficiency
Collagen disease
Endocrine and metabolic disorders
Infections (eg, syphilis)
Widespread skin disease

Because most scalp hair is in anagen at a given time, and telogen effluvium is dependent on the transition from anagen to telogen, with subsequent release of telogen hairs, it has a latent period of months, and the hair loss is usually subclinical, involving less than 50% of hairs.^[2]

Reversible alopecia following chemotherapy is common. However, permanent chemotherapy-induced alopecia, has been described, with a unique histologic finding of replacement of anagen hair follicles by linear columns of basaloid epithelium.^[21]Although anagen effluvium due to chemotherapy is usually reversible with complete hair regrowth, certain chemotherapy regimens can cause dose-dependent permanent alopecia with histological features of nonscarring alopecia similar to androgenetic alopecia.^[22]

Profuse hair shedding may reveal anagen hair dystrophy, representing a diagnostic clue of incipient alopecia areata.^[23]

Hair disorders with autoimmune connective-tissue diseases may uncommonly resemble anagen effluvium.^[24]

Differential Diagnoses

Workup

Gilmore S, Sinclair R. Chronic telogen effluvium is due to a reduction in the variance of anagen duration. Australas J Dermatol. 2010 Aug. 51(3):163-7. [Medline].
Trueb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009 Mar. 28(1):11-4. [Medline].
Delmonte S, Semino MT, Parodi A, Rebora A. Normal anagen effluvium: a sign of pemphigus vulgaris. Br J Dermatol. 2000 Jun. 142(6):1244-5. [Medline].
Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol. 1983 Nov. 9(5):645-63. [Medline].
Tosi A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf. 1994 Apr. 10(4):310-7. [Medline].
Tosti A, Pazzaglia M. Drug reactions affecting hair: diagnosis. Dermatol Clin. 2007 Apr. 25(2):223-31. [Medline].
Cardoza-Torres MA, Liy-Wong C, Welsh O, Gómez-Flores M, Ocampo-Candiani J, González-Llano O, et al. Skin Manifestations Associated with Chemotherapy in Children with Hematologic Malignancies. Pediatr Dermatol. 2011 Nov 2. [Medline].
Biswal SG, Mehta RD. Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian J Dermatol. 2018 Jan-Feb. 63 (1):41-46. [Medline].
Sonthalia S, Daulatabad D. Azathioprine-associated anagen effluvium. Indian J Dermatol Venereol Leprol. 2016 May-Jun. 82 (3):322-4. [Medline].
Łukasik A, Kozicka K, Wojas-Pelc A. The influence of methotrexate on hair loss while using immunomodulatory doses. Pol Merkur Lekarski. 2019 Feb 28. 46 (272):77-79. [Medline].
Lee YY, Yang CH, Chen CH, Hwang JS. Alopecia associated with strontium ranelate use in a 62-year-old woman. Osteoporos Int. 2013 Mar. 24(3):1127-9. [Medline].
Turker K, Tas B, Ozkaya M, Tas E, Caglar A, Tetikkurt US. Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-a-2a/Ribavirin Therapy. Hepat Mon. 2015 Mar. 15(3):e24804. [Medline]. [Full Text].
Combalia A, Baliu-Piqué C, Fortea A, Ferrando J. Anagen Effluvium Following Acute Colchicine Poisoning. Int J Trichology. 2016 Oct-Dec. 8 (4):171-172. [Medline].
Ghias MH, Amin BD, Kutner AJ. Albendazole-induced anagen effluvium. JAAD Case Rep. 2020 Jan. 6 (1):54-56. [Medline].
Fonia A, Cota C, Setterfield JF, Goldberg LJ, Fenton DA, Stefanato CM. Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol. 2017 May. 76 (5):948-957. [Medline].
Campbell C, Bahrami S, Owen C. Anagen Effluvium Caused by Thallium Poisoning. JAMA Dermatol. 2016 Jun 1. 152 (6):724-6. [Medline].
Irune E, Bast F, Williams G, Kirkpatrick N. Recovery of Transplanted Eyebrow From Radiation-Induced Anagen Effluvium. J Cutan Med Surg. 2015 Mar 16. [Medline].
Choi MJ, Kim DY, Kim JS, Kim H, Cho SB. Acute vesiculobullous hand dermatitis and anagen effluvium in Ganoderma lucidum-induced aplastic crisis. Ann Hematol. 2013 Mar 10. [Medline].
Patel M, Harrison S, Sinclair R. Drugs and hair loss. Dermatol Clin. 2013 Jan. 31(1):67-73. [Medline].
Kanti V, Nuwayhid R, Lindner J, Hillmann K, Stroux A, Bangemann N, et al. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study. Br J Dermatol. 2014 Mar. 170(3):643-50. [Medline].
Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: Case report and review of the literature. J Am Acad Dermatol. 2010 May 12. [Medline].
Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P, Tosti A. Permanent Alopecia After Systemic Chemotherapy: A Clinicopathological Study of 10 Cases. Am J Dermatopathol. 2011 Mar 11. [Medline].
Quercetani R, Rebora AE, Fedi MC, Carelli G, Mei S, Chelli A, et al. Patients with profuse hair shedding may reveal anagen hair dystrophy: a diagnostic clue of alopecia areata incognita. J Eur Acad Dermatol Venereol. 2011 Jul. 25(7):808-10. [Medline].
Cassano N, Amerio P, D'Ovidio R, Vena GA. Hair disorders associated with autoimmune connective tissue diseases. G Ital Dermatol Venereol. 2014 Oct. 149(5):555-65. [Medline].
van Beek N, Bodo E, Kromminga A, et al. Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. J Clin Endocrinol Metab. 2008 Nov. 93(11):4381-8. [Medline].
Trovato MJ, Schwartz RA, Janniger CK. Tinea capitis: current concepts in clinical practice. Cutis. 2006 Feb. 77(2):93-9. [Medline].
Olszewska M, Warszawik O, Rakowska A, Slowinska M, Rudnicka L. [Methods of hair loss evaluation in patients with endocrine disorders]. Endokrynol Pol. 2011. 62 Suppl 1:29-34. [Medline].
Uce Özkol H, Çalka Ö, Akdeniz N. Is TrichoScan a new diagnostic method for diffuse hair loss?. Turk J Med Sci. 2014. 44(3):432-8. [Medline].
Duvic M, Lemak NA, Valero V, Hymes SR, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996 Jul. 35(1):74-8. [Medline].
Anzai A, Pereira AF, Malaquias KR, Guerra LO, Mercuri M. Efficacy and safety of a new formulation kit (shampoo + lotion) containing anti-inflammatory and antioxidant agents to treat hair loss. Dermatol Ther. 2020 Mar 5. e13293. [Medline].
Merial-Kieny C, Nocera T, Mery S. [Medical corrective make-up in post- chemotherapy]. Ann Dermatol Venereol. 2008 Jan. Spec No 1:25-8. [Medline].
Bleiker TO, Nicolaou N, Traulsen J, Hutchinson PE. 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans. Br J Dermatol. 2005 Jul. 153 (1):103-12. [Medline].
Jimenez JJ, Roberts SM, Mejia J, et al. Prevention of chemotherapy-induced alopecia in rodent models. Cell Stress Chaperones. 2008 Spring. 13(1):31-8. [Medline]. [Full Text].

Media Gallery

Anagen effluvium. Courtesy of DermNet New Zealand (https://www.dermnetnz.org/assets/Uploads/hair-nails-sweat/anagen-effluvium-01.jpg).

of 1

Author

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, New York Academy of Medicine, Royal College of Physicians of Edinburgh, Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Pere Gascon, MD, PhD Professor and Director, Division of Medical Oncology, Institute of Hematology and Medical Oncology, IDIBAPS, University of Barcelona Faculty of Medicine, Spain

Pere Gascon, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, New York Academy of Medicine, New York Academy of Sciences, Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society for MOHS Surgery, Association of Military Dermatologists, Phi Beta Kappa

Disclosure: Nothing to disclose.

Rosalie Elenitsas, MD Herman Beerman Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System

Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society of Dermatopathology, Pennsylvania Academy of Dermatology

Disclosure: Received royalty from Lippincott Williams Wilkins for textbook editor.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Acknowledgements

Günter Burg, MD Professor and Chairman Emeritus, Department of Dermatology, University of Zürich School of Medicine; Delegate of The Foundation for Modern Teaching and Learning in Medicine Faculty of Medicine, University of Zürich, Switzerland

Günter Burg, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, International Society for Dermatologic Surgery, North American Clinical Dermatologic Society, and Pacific Dermatologic Association

Disclosure: Nothing to disclose.

Bryan D Seiff, MD Staff Physician, Department of Ophthalmology, NY Presbyterian Hospital-Cornell

Bryan D Seiff, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Anagen Effluvium Differential Diagnoses

Diagnostic Considerations

Differential Diagnoses

About

Membership

Apps

WebMD Network

Editions

Anagen Effluvium Differential Diagnoses

Diagnostic Considerations

Differential Diagnoses

References

Tables

Contributor Information and Disclosures

What would you like to print?

Find Us On

About

Membership

Apps

WebMD Network

Editions